Yale Cancer Center (YCC) is one of only 56 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.
Personalizing Cancer Drugs: The Next Front in Diagnostics
October 28th 2015Less than a decade after the FDA set the ground rules for developing assays that pair molecular targets with new drugs, experts say there have been strides in personalizing anticancer therapies but that many hurdles remain before next-generation sequencing and other precision medicine advances are incorporated into the diagnostic paradigm.
Dr. Patricia LoRusso on Next-Generation Sequencing Benefit in Metastatic Melanoma Treatment
October 16th 2015Patricia M. LoRusso, DO, Professor of Medicine and Associate Director of Innovative Medicine, Yale Cancer Center, discusses taking a personalized medicine approach to treat melanoma patients whose tumors do not have BRAF alterations.
Yale Cancer Center Receives $11 Million From National Cancer Institute for Lung Cancer Research
Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven will launch a new research program in non-small cell lung cancer, one of the world's most prevalent and lethal forms of cancer.
Dr. Pusztai Discusses BCI in Patients With ER-Positive/HR-Positive Breast Cancer
August 18th 2015Lajos Pusztai, MD, DPhil, professor of Medicine (Medical Oncology), chief, Breast Medical Oncology, co-director, Cancer Genetics Research Program, Yale Cancer Center, discusses the Breast Cancer Index in patients with ER-positive/HR-positive breast cancer.
Dr. Chagpar on Sequencing Therapies for HER2-Positive Breast Cancer
August 3rd 2015Anees B. Chagpar, MD, MA, MPH, MBA, FRCS(C), FACS, associate professor of surgery (oncology), director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses sequencing therapies for patients with HER2-positive breast cancer.
Novel Radium-223 Combinations on the Horizon in Bone-Metastatic CRPC
Novel combination approaches are currently under exploration that hope to capitalize on the varying mechanisms of action for each newly approved agent for men with metastatic castration-resistant prostate cancer.
Melinda Irwin on Impact of Exercise on Survivors' Quality of Life
June 15th 2015Melinda Liggett Irwin, PhD, MPH, associate professor of epidemiology (chronic diseases), Yale School of Public Health, co-program leader, Cancer Prevention and Control Research Program, Yale Cancer Center, discusses the impact of the LIVESTRONG at the YMCA Program on survivors' fitness, physical activity, and quality of life.
Dr. Kapo on Addressing Palliative Care With Patients
April 29th 2015Jennifer M. Kapo, MD, chief, palliative medicine, Yale Cancer Center, associate professor of medicine (medical oncology and geriatrics), Yale School of Medicine, discusses how oncologists can address palliative care with their patients.
Yale Launches National Study of Personalized Medicine for Metastatic Melanoma
Yale University has launched a multicenter clinical trial, sponsored by Stand Up to Cancer and Melanoma Research Alliance, that will apply the latest in personalized medicine technology to treat metastatic melanoma.
Dr. Irwin on Exercise and Weight Loss After Breast Cancer Diagnosis
April 6th 2015Melinda L. Irwin, PhD, MPH, associate professor, Yale School of Public Health, co-program leader, Cancer Prevention and Control Research Program, Yale Cancer Center, discusses the results of a study she conducted examining the effects of exercise and weight loss in patients with breast cancer.
Lung Cancer Pioneer Thomas Lynch Discusses the State of the Art
April 2nd 2015Thomas Lynch, who is director of the Yale Cancer Center and physician-in-chief at the Smilow Cancer Hospital at Yale-New Haven, recently sat down with OncLive and discussed key strategies and trends in the management of lung cancer.
Yale Scientist Wins International Award for Discoveries Leading to New Class of Cancer Drugs
A Spanish foundation has awarded a major scientific prize to Yale researcher Joseph Schlessinger and two colleagues in recognition of their work leading to the first personalized treatments for cancer. The 2015 Frontiers of Knowledge Award in Biomedicine from the Madrid-based BBVA Foundation includes a €400,000 cash priz